Research
Hormonal
Tirzepatide 15 mg and semaglutide 1.0 mg, when added to metformin in type 2 diabetes, provide superior HbA1c reduction and weight loss compared to other GLP-1 receptor agonists, without increasing hypoglycemia risk.
For patients with Type 2 Diabetes on Metformin, Tirzepatide 15mg and Semaglutide 1.0mg are the most effective options for lowering blood sugar and losing weight among GLP-1 agonists. They do not increase hypoglycemia risk. If injections are a barrier, oral Semaglutide 14mg is a viable alternative with good efficacy.
StrongSupportsHIGH confidence
According to the NMA, tirzepatide 15 mg, semaglutide 1.0 mg... reduced HbA1c by -2.23%, -1.57%... and body weight by -11.33 kg, -5.99 kg... All GLP-1RA did not lead to increased incidence of hypoglycemia.
Why this rating
Network meta-analysis of 34 RCTs with 12,993 patients.
Source
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Zeyu Xie et al. · Frontiers in Endocrinology · 2023
Meta-analysis · 34 studiesCited 43×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →